New Advances on Prostate Carcinogenesis and Therapies: Involvement of EGF-EGFR Transduction System

REFERENCES

• Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Mascara, J.M., Herbst, R., LoRusso, P., Rischin, D., Sauleda, S., Gee, J., Nicholson, R.I. and Baselga, J. (2002) “Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZDl839 in skin from cancer patients: histopathologic and molecular consequence of receptor inhibition”, J. Clin. Oncol. 20, 110–124.
   PubMed Web of Science ®Google Scholar
• Alper, O., Hacker, N.F. and Cho-Chung, Y. (1999) “Protein kinase A-Ia subunit-directed antisense inhibition of ovarian cancer cell growth: cross-talk with tyrosine kinase signaling pathway”, Oncogene 18, 4999–5004.
   PubMed Web of Science ®Google Scholar
• Anderson, R.G.W. (1998) “The caveolae membrane system”, Annu. Rev. Biochem. 67, 199–225.
   PubMed Web of Science ®Google Scholar
• Aquilina, J.W., Lipsky, J.J. and Bostwick, D.G. (1997) “Androgen deprivation as a strategy for prostate cancer chemoprevention”, J. Natl Cancer Inst. 89, 689–696.
   PubMedGoogle Scholar
• Attiga, F.A., Femandez, P.M., Weeraratna, A.T., Manyak, M.J. and Patierno, S.R. (2000) “Inhibitors of prostanglandin synthesis inhibit human tumor cell invasiveness and reduce the release of matrix metalloproteases”, Cancer Res. 60, 4629–4637.
   PubMed Web of Science ®Google Scholar
• Bakhle, Y.S. (2001) “COX-2 and cancer: a new approach to an old problem”, Br. J. Pharmacol. 134, 1137–1150.
   PubMed Web of Science ®Google Scholar
• Banerjee, P-P., Banerjee, S. and Brown, T.R. (2002) “Bcl-2 protein expression correlates with cell survival and androgen independence in rat prostatic lobes”, Endocrinology 143, 1825–1832.
   PubMed Web of Science ®Google Scholar
• Barki-Harrington, L. and Daaka, Y. (2001) “Bradykinin induced mitogenesis of androgen independent prostate cancer cells”, J. Urol. 165, 2121–2125.
   PubMed Web of Science ®Google Scholar
• Barton, J., Blackledge, G. and Wakeling, A. (2001) “Growth factors and their receptors: new targets for prostate cancer therapy”, Urology 58, 114–122.
   PubMed Web of Science ®Google Scholar
• Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D.G., Kaye, S.B., Gianni, L., Harris, A., Bjork, T., Averbuch, S.D., Feyereislova, A., Swaisland, H., Rojo, F. and Albanell, J. (2002) “Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine inhibitor, in patients with five selected solid tumor types”, J. Clin. Oncol. 20, 4276–4278.
   PubMedGoogle Scholar
• Bello-DeOcampo, D., Kleinman, H.K. and Webber, M.M. (2001) “The role of alpha 6 and beta 1 integrin and EGF in normal and malignant acinar morphogenesis of human prostatic epithelial cells”, Mutat. Res. 480–481, 209–217.
   Google Scholar
• Bergan, R.C., Waggle, D.H., Carter, S.K., Horak, I., Slichenmyer, W. and Meyers, M. (2001) “Tyrosine kinase inhibitors and signal transduction modulators: rationale and current status as chemopreventive agents for prostate cancer”, Urology 57, 77–80.
   PubMedGoogle Scholar
• Bianco, C., Bianco, R., Tortora, G., Damiano, V., Guerrieri, P., Montemaggi, P., Mendelsohn, J., De Placido, S., Bianco, A.R. and Ciardiello, F. (2000) “Antitumor activity of combined treatment of human cancer with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide”, Clin. Cancer Res. 6, 4343–4350.
   PubMed Web of Science ®Google Scholar
• Brown, D.A. and London, E. (2000) “Structure and function of sphingolipid-and cholesterol-rich membrane rafts”, J. Biol. Chem. 275, 17221–17224.
   PubMed Web of Science ®Google Scholar
• Bruchovsky, N., Klotz, L.H., Sadar, M., Crook, J.M., Hoffard, D., Godwin, L., Warkentin, M., Gleave, M.E. and Goldenberg, S.L. (2000) “Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations”, Mol. Urol. 4, 191–199.
   PubMedGoogle Scholar
• Chan, K.C., Knox, W.F., Gee, J.M., Morris, J., Nicholson, R.I., Potten, C.S. and Bundred, N.J. (2002) “Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast”, Cancer Res. 62, 122–128.
   PubMed Web of Science ®Google Scholar
• Chaudhary, K.S., Abel, P.D. and Lalani, E.N. (1999) “Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention”, Environ. Health Perspect. 107, 49–57.
   PubMed Web of Science ®Google Scholar
• Chen, Y. and Hughes-Fulford, M. (2000) “Prostaglandin E2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cells”, Br. J. Cancer 82, 2000–2006.
   PubMed Web of Science ®Google Scholar
• Chen, T., Cho, R.W., Stork, P.J. and Weber, M.J. (1999) “Elevation of cyclic adenosine 30,50-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells”, Cancer Res. 59, 213–218.
   PubMed Web of Science ®Google Scholar
• Chi, K.N., Gleave, M.E., Klasa, R., Murray, N., Bryce, C., Lopes de Menezes, D.E., D’Aloisio, S. and Tolcher A.W. (2001) “A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer”, Clin. Cancer Res. 7, 3920–3927.
   Google Scholar
• Cho, Y.S., Lee, Y.N. and Cho-Chung, Y.S. (2000) “Biochemical characterization of extracellular cAMP-dependent protein kinase as a tumor marker”, Biochem. Biophys. Res. Commun. 278, 679–684.
   PubMedGoogle Scholar
• Cho, Y.S., Kim, M.K., Tan, L., Srivastava, R., Agrawal, S. and Cho-Chung, Y.S. (2002) “Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphos phorylation. Bax up-regulation, and Bad-hypophosphorylation”, Clin. Cancer Res. 8, 607–614.
   PubMed Web of Science ®Google Scholar
• Ciardiello, F. and Tortora, G. (1998) “Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications”, Clin. Cancer Res. 4, 821–828.
   PubMed Web of Science ®Google Scholar
• Ciardiello, F. (2000) “Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents”, Drugs 60, 25–32.
   PubMed Web of Science ®Google Scholar
• Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Pomatico, G., De Placido, S., Bianco, A.R. and Tortora, G. (2000) “Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor”, Clin. Cancer Res. 6, 2053–2063.
   PubMed Web of Science ®Google Scholar
• Coffey, R.N., Watson, R.W., Hegarty, P.K., Waston, C.L., Wolohan, L., Brady, H.R., O’Keane, C. and Fitzpatrick, J.M. (2001) “Priming prostate carcinoma cells for increased apoptosis is associated with up-regulation of the caspases”, Cancer 92, 2297–2308.
   PubMed Web of Science ®Google Scholar
• Coffey, R.N., Watson, R.W., O’Neill, A.J., Mc Eleny, K. and Fitzpatrick, J.M. (2002) “Androgen-mediated resistance to apoptosis”, Prostate 53, 300–309.
   PubMedGoogle Scholar
• Condorelli, F., Canonico, P.L. and Sortino, M.A. (1999) “Distinct effects of ceramide-generating pathways in prostate adenocarcinoma”, Br. J. Pharmacol. 127, 75–84.
   PubMed Web of Science ®Google Scholar
• Coroneos, E., Martinez, M., McKenna, S. and Kester, M. (1995) “Differential regulation of sphingomyelinase and ceramidase activities by growth factors and cytokines. Implications for cellular proliferation and differentiation”, J. Biol. Chem. 270, 23305–23309.
   PubMed Web of Science ®Google Scholar
• Cox, M.E., Deeble, P.D., Bissonette, E.A. and Parsons, S.J. (2000) “Activated 30,50-cyclic AMP-dependent protein kinase is sufficient to induce neuroendocrine-like differentiation of the LNCaP prostate tumor cell line”, J. Biol. Chem. 275, 13812–13818.
   PubMed Web of Science ®Google Scholar
• Cuendet, M. and Pezzuto, J.M. (2000) “The role of cyclooxygenase and lipoxygenase in cancer chemoprevention”, Drug Metabol. Drug Interact. 17, 109–157.
   PubMedGoogle Scholar
• Culig, Z., Hobisch, A., Hittmair, A., Peterziel, H., Radmayr, C., Bartsch, G., Cato, A.C. and Klocker, H. (1997) “Hyperactive androgen receptor in prostrate cancer: what does it mean for new concepts?”, Histol. Histopathol. 12, 781–786.
   PubMedGoogle Scholar
• Culig, Z., Hobisch, A., Bartsch, G. and Klocker, H. (2000) “Expression and function of androgen receptor in carcinoma of the prostate”, Microsc. Res. Tech. 51, 447–455.
   PubMed Web of Science ®Google Scholar
• Cvijic, M.E., Kita, T., Shih, W., DiPaola, R.S. and Chin, K.V. (2000) “Extracellular catalytic subunit activity of the cAMP-dependent protein kinase in prostate cancer”, Clin. Cancer Res. 6, 2309–2317.
   PubMedGoogle Scholar
• Daaka, Y. (2002) “Mitogenic action of LPA in prostate”, Biochim. Biophys. Acta 1582, 265–269.
   PubMedGoogle Scholar
• Datta, S.R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y. and Greenberg, M.E. (1997) “Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery”, Cell 91, 231–241.
   PubMed Web of Science ®Google Scholar
• De Bellis, A., Ghiandi, P., Comerci, A., Fiorelli, G., Grappone, C., Milani, S., Salerno, R., Marra, F. and Serio, M. (1996) “Epidermal growth factor, epidermal growth factor receptor, and transforming growth factor-alpha in human hyperplastic prostate tissue: expression and cellular localization”, J. Clin. Endocr. Metab. 81, 4148–4154.
   PubMedGoogle Scholar
• Del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R. and Nunez, G. (1997) “Interleukin-3 induced phosphorylation of BAD through the protein kinase Akt”, Science 278, 687–689.
   PubMed Web of Science ®Google Scholar
• Demers, R.Y., Tiwari, A., Wei, J., Weiss, L.K., Severson, R.K. and Montie, J. (2001) “Trends in the utilization of androgen-deprivation therapy for patients with prostate carcinoma suggest an effect on mortality”, Cancer 92, 2309–2317.
   PubMedGoogle Scholar
• De Miguel, P., Royuela, M., Bethencourt, R., Ruiz, A., Fraile, B. and Paniagua, R. (1999) “Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates”, Cytokine 11, 722–727.
   PubMed Web of Science ®Google Scholar
• Denmeade, S.R. and Isaacs, J.T. (1996) “Activation of programmed (apoptotic) cell death for the treatment of prostate cancer”, Adv. Pharmacol. 35, 281–306.
   PubMedGoogle Scholar
• Di Lorenzo, G., Tortora, G., D’ Armiento, F.P., De Rosa, G., Staibano, S., Autorino, R., D’ Armiento, M., De Laurentiis, M., De Placido, S., Catalano, G., Bianco, A.R. and Ciardiello, F. (2002) “Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer”, Clin. Cancer Res. 8, 3438–3444.
   PubMed Web of Science ®Google Scholar
• Dong, J., Opresko, L.K., Dempsey, P.J., Lauffenburger, D.A., Coffey, R.J. and Wiley, H.S. (1999) “Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor”, Proc. Natl Acad. Sci. (USA) 96, 6235–6240.
   PubMed Web of Science ®Google Scholar
• Dorai, T., Gehani, N. and Katz, A. (2000) “Therapeutic potential of curcumin in human prostate cancer II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein”, Mol. Urol. 4, 1–6.
   PubMedGoogle Scholar
• Dorai, T., Cao, Y.C., Dorai, B., Buttyan, R. and Katz, A.E. (2001) “Therapeutic potential of curcumin in human prostate cancer III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo”, Prostate 47, 293–303.
   PubMed Web of Science ®Google Scholar
• Dotzlaw, H., Moehren, U., Mink, S., Cato, A.C., Iniguez Lluhi, J.A. and Baniahmad, A. (2002) “The amino terminus of the human AR is target for corepressor action and antihormone agonism”, Mol. Endocrinol. 16, 661–673.
   PubMedGoogle Scholar
• Edamatsu, H., Gau, C.L., Nemoto, T., Guo, I. and Tamanoi, F. (2000) “Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines”, Oncogene 19, 3059–3068.
   PubMed Web of Science ®Google Scholar
• Engedal, N. and Saatcioglu, F. (2000) “Ceramide-induced cell death in the prostate cancer cell line LNCaP has both necrotic and apoptotic features”, Prostate 46, 289–297.
   Google Scholar
• Feldman, B.J. and Feldman, D. (2001) “The development of androgen-independent prostate cancer”, Nat. Rev. Cancer 1, 34–45.
   PubMed Web of Science ®Google Scholar
• Fishman, D., Galitzki, L., Priel, E. and Segal, S. (1997) “Epidermal growth factor regulates protein kinase A activity in marine fibrosarcoma cells: differences between metastatic and nonmetastatic tumor cell variants”, Cancer Res. 57, 5410–5415.
   PubMedGoogle Scholar
• Fujita, H., Koshida, K., Keller, E.T., Takahashi, Y., Yoshimito, T., Namiki, M. and Mizokami, A. (2002) “Cyclooxygenase-2 promotes prostate cancer progression”, Prostate 53, 232–240.
   Google Scholar
• Gallardo, G., Tabraue, C., Quintana, J., Lopez-Bianco, F., Cabrera, J., Diaz, R., Estevez, F., Ruiz de Galarreta C.M., Fanjul L.F. and Santana P. (2000) “Regulation by ceramide of epidermal growth factor signal transduction and mitogenesis in cell lines overespressing the growth factor receptor”, Cell Mol. Biol. 46, 1305–1312.
   Google Scholar
• Garzotto, M., Haimovitz-Friedman, A., Liao, W.C., White-Jones, M., Huryk, R., Heston, W.D., Cardon-Cardo, C., Kolesnick, R. and Fuks, Z. (1999) “Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthetase”, Cancer Res. 59, 5194–5201.
   PubMed Web of Science ®Google Scholar
• Gewies, A., Rokhlin, O.W. and Cohen, M.B. (2000) “Ceramide induces cell death in the human prostatic carcinoma cell lines PC3 and DU145 but does not seem to be involved in Fas-mediated apoptosis”, Lab. Investig. 80, 671–676.
   PubMedGoogle Scholar
• Ghosh, P.M., Bedolla, R., Mikhailova, M. and Kreisberg, J.I. (2002) “RhoA-dependent murine prostate cancer cell proliferation and apoptosis: role of protein kinase Czeta”, Cancer Res. 62, 2630–2636.
   PubMed Web of Science ®Google Scholar
• Gil-Diez de Medina, S., Salomon, L., Colombel, M., Abbou, C.C., Bellot, J., Thiery, J.P., Radvanyi, F., Van der Kwast, T.H. and Chopin D.K. (1998) “Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer”, Hum. Pathol. 29, 1005–1012.
   Google Scholar
• Gleave, M.E., Zeilweger, T., Chi, K., Miyake, H., Kiyama, S., July, I. and Leung, S. (2002) “Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen-and chemo-sensibility”, Invest. New Drug 20, 145–158.
   PubMedGoogle Scholar
• Glynne-Jones, E., Goddard, L. and Harper, M.E. (1996) “Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue”, Hum. Pathol. 27, 688–694.
   PubMedGoogle Scholar
• Graff, J.R. (2002) “Emerging targets in the AKT pathways for treatment of androgen-independent prostatic adenocarcin–oma”, Expert Opin. Ther. Targets 6, 103–113.
   PubMedGoogle Scholar
• Gschwind, A., Zwick, E., Prenzel, N., Leserer, M. and Ullrich, A. (2001) “Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for inter-receptor signal transmission”, Oncogene 20, 1594–1600.
   PubMed Web of Science ®Google Scholar
• Hafner, S., Adler, H.S., Mischak, H., Janosch, P., Heidecker, G., Wolfman, A., Piggig, S., Lohse, M., Ueffing, M. and Kolch, W. (1994) “Mechanism of inhibition of Raf-1 by protein kinase A”, Mol. Cell. Biol. 14, 6696–6703.
   PubMedGoogle Scholar
• Harper, M.E., Goddard, L., Glynne-Jones, E., Assender, J., Dutkowski, C.M., Barrow, D., Dewhurst, O.L., Waketing, A.E. and Nicholson, R.I. (2002) “Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor”, Prostate 52, 59–68.
   PubMedGoogle Scholar
• Hellerstedt, B-A. and Pienta, K.J. (2002) “The current state of hormonal therapy for prostate cancer CA”, Cancer J. Clin. 52, 154–179.
   Google Scholar
• Herbst, R.S. (2002) “ZD1839: targeting the epidermal growth factor receptor in cancer therapy”, Expert Opin. Investig. Drugs 11, 837–849.
   Google Scholar
• Herrmann, J.L., Menter, D.G., Beham, A., Von Eschenbach, A. and McDonnell, T.G. (1997) “Regulation of lipid signaling pathways for cell survival and apoptosis by bcl-2 in prostate carcinoma cells”, Exp. Cell. Res. 234, 442–451.
   PubMedGoogle Scholar
• Hoosein, N.M., Logothetis, C.J. and Chung, L.W. (1993) “Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells”, J. Urol. 149, 1209–1213.
   PubMed Web of Science ®Google Scholar
• Huang, H. and Tindall, D.J. (2002) “The role of the androgen receptor in prostate cancer”, Crit. Rev. Eukaryot. Gene Expr. 12, 193–207.
   PubMed Web of Science ®Google Scholar
• Johnson, K.P., Rowe, G.C., Jackson, B.A., d’Agustino J.L., Campbell P.E., Guillory B.O., Williams M.V., Matthews Q.L., McKay J., Charles G.M., Vet-ret C.R., Deleon M., Johnson D.E. and Cooke D.B. (2002) “Novel antineoplastic isochalcones inhibit the expression of cyclooxygenase 1,2 and EGF in human prostate cancer line LNCaP”, Cell. Mol. Biol. 47, 1039–1045.
   Google Scholar
• Kamijo, T., Sato, T., Nagatomi, Y. and Kitamura, T. (2001) “Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines”, Int. J. Urol. 8, S35–S39.
   PubMed Web of Science ®Google Scholar
• Karashima, T., Sweeney, P., Slaton, J.M., Kim, S.J., Kedar, D., Izawa, J.I., Fan, Z., Pettaway, C., Hicklin, D.J., Shuin, T. and Dinney, C.P. (2002) “Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice”, Clin. Cancer Res. 8, 1253–1264.
   PubMed Web of Science ®Google Scholar
• Karp, J.E., Chiarodo, A., Brawley, O. and Kelloff, G.F. (1996) “Prostate cancer prevention: investigational approaches and opportunities”, Cancer Res. 56, 5547–5556.
   PubMed Web of Science ®Google Scholar
• Karunagaran, D., Tzahar, E., Beerli, R.R., Chen, X., Graus-Porta, D., Ratzkin, B.J., Seger, R., Hynes, N.E. and Yarden, Y. (1996) “ErbB-2 is a commun auxiliary subunit of NDF and EGF receptors: implications for breast cancer”, EMBO J. 15, 254–264.
   PubMed Web of Science ®Google Scholar
• Kelloff, G.J., Lieberman, R., Steele, V.E., Boone, C.W., Lubel, R.A., Kepelovich, I., Malone, W.A., Crowell, J.A., Higley, H.R. and Sigman, C.C. (2001) “Agents, biomarkers, and cohorts for chemopreventive agent development in prostrate cancer”, Urology 57, 46–51.
   PubMed Web of Science ®Google Scholar
• Kim, H.G., Kassis, I., Sorrto, J.C., Turner, T. and Wells, A. (1999) “EGF receptor signaling in prostate morphogenesis and tumorigenesis”, Histol. Histopathol. 14, 1175–1182.
   PubMedGoogle Scholar
• Kim, E-S., Khuri, F.R. and Herbst, R.S. (2001) “Epidermal growth factor receptor biology (IMC-C225)”, Curr. Opin. Oncol. 13, 506–513.
   PubMed Web of Science ®Google Scholar
• Kimura, K., Markowski, M., Bowen, C. and Gelmann, E.P. (2001) “Androgen blocks apoptosis of hormone-dependent prostate cancer cells”, Cancer Res. 61, 5611–5618.
   PubMed Web of Science ®Google Scholar
• Kirschenbaum, A., Liu, X., Yao, S. and Levine, A.C. (2001) “The role of cyciooxygenease-2 in prostate cancer”, Urology 58, 127–131.
   PubMed Web of Science ®Google Scholar
• Klocker, H., Culig, Z., Eder, I.E., Nessler-Menardi, C., Hobisch, A., Putz, T., Bartsch, G., Peterziel, H. and Cato, A.C. (1999) “Mechanism of androgen receptor activation and possible implications for chemoprevention trials”, Eur. Urol. 35, 413–419.
   PubMed Web of Science ®Google Scholar
• Konety, B.R. and Nelson, J.B. (2001) “Nonandrogenic mediators of prostatic growth”, Hematol. Oncol. Clin. North Am. 15, 459–476.
   PubMedGoogle Scholar
• Kranenburg, O. and Moolenaar, W.H. (2001) “Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists”, Oncogene 20, 1540–1546.
   PubMed Web of Science ®Google Scholar
• Kue, P.F. and Daaka, Y. (2000) “Essential role for G proteins in prostate cancer cell growth and signaling”, J. Urol. 164, 2162–2167.
   PubMedGoogle Scholar
• Kue, P.F., Taub, J.S., Harrington, L.B., Polakiewicz, R.D., Ullrich, A. and Daaka, Y. (2002) “Lysophosphatidic acid-regulated mitogenic ERK signaling in androgen-insensitive prostate cancer PC-3 cells”, Int. J. Cancer 102, 572–579.
   PubMedGoogle Scholar
• Kumar, V.L., Majumder, P.K., Gujral, S. and Kumar, V. (1998) “Comparative analysis of epidermal growth factor receptor mRNA levels in normal, benign hyperplastic and carcimatous prostate”, Cancer Lett. 134, 177–180.
   PubMedGoogle Scholar
• Kyprianou, N. (1994) “Apoptosis: therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer”, World J. Urol. 12, 299–303.
   PubMed Web of Science ®Google Scholar
• Lalani, E.N., Laniado, M.E. and Abel, P.D. (1997) “Molecular and cellular biology of prostate cancer”, Cancer Metast. Rev. 16, 29–66.
   Google Scholar
• Li, M.T., Richter, F., Chang, C., Irwin, R.J. and Huang, H. (2002) “Androgen and retinoic acid interaction in LNCaP cells, effects on cell proliferation and expression of retinoic acid receptors and epidermal growth factor receptor”, BMC Cancer 2, 16.
   PubMedGoogle Scholar
• Lin, J., Adam, R.M., Santiestevan, E. and Freeman, M.R. (1999) “The phosphatidylinositol 30-kinase pathway is a dominant growth factoractivated cell survival pathway in LNCaP human prostate carcinoma cells”, Cancer Res. 59, 2891–2897.
   PubMed Web of Science ®Google Scholar
• Liu, W.K., Wong, N.L., Huang, H.M., Ho, J.K., Zhang, W.H. and Che, C.T. (2002) “Growth inhibitory activity of lemnabourside on human prostate cancer cells”, Life Sci. 70, 843–853.
   PubMedGoogle Scholar
• Liu, X.H., Wiley, H.S. and Merkle, A.W. (1993) “Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor”, J. Clin. Endocr. Metab. 77, 1472–1478.
   PubMedGoogle Scholar
• Liu, X.H., Kirschenbaum, A., Yao, S., Lee, R., Holland, J.F. and Levine, A.C. (2000) “Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo”, J. Urol. 164, 820–825.
   PubMed Web of Science ®Google Scholar
• Liu, X.H., Kirschenbaum, A., Lu, M., Yao, S., Dosoretz, A., Holland, J.F. and Levine, A.C. (2002) “Prostaglandin E2 induces hypoxia-inducible factor-1a stabilization and nuclear localization in a prostate cancer cell line”, J. Biol. Chem. Lu, X.F., Tam, N.C. and Wong, Y.C. (2000) “Roles of growth factors in mediating mesenchymal influence on the cytodifferentiation of the Dunning prostatic adenocarcinoma”, Tumour Biol. 21, 21–32.
   Google Scholar
• MacDonald, A. and Habid, F.K. (1992) “Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines”, Br. J. Cancer 65, 177–182.
   PubMed Web of Science ®Google Scholar
• Maddy, S.Q., Chisholm, G.D., Busuttil, A. and Habib, F.K. (1989) “Epidermal growth factor receptors in prostate cancer: correlation with histological differentiation of the tumour”, Br. J. Cancer 60, 41–44.
   PubMed Web of Science ®Google Scholar
• Marinissen, M.J. and Gutkind, J.S. (2001) “G-protein-coupled receptors and signaling networks: emerging paradigms”, Trends Pharmacol. Sci. 22, 368–376.
   Google Scholar
• Melck, D., Rueda, D., Galve-Roperh, I., De Petrocellis, L., Guzman, M. and Di Marzo, V. (1999) “Involvement of the cAMP/protein kinase pathway and of mitogen-activated protein-kinase in the anti-proliferative effects of anandamide in human breast cancer cells”, FEBS Lett. 463, 235–240.
   PubMed Web of Science ®Google Scholar
• Melck, D., De Petrocellis, L., Orlando, P., Bisogno, T., Laezza, C., Bifulco, M. and Di Marzo, V. (2000) “Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation”, Endocrinology 141, 118–126.
   PubMed Web of Science ®Google Scholar
• Mellinghoff, I.K., Tran, C. and Sawyers, C.L. (2002) “Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts”, Cancer Res. 62, 5254–5259.
   PubMed Web of Science ®Google Scholar
• Meric, J.B., Faivre, S., Monnerat, C., diVago N.A., Le Chevalier T., Armand J.P. and Raymond E. (2000) “ZD1839: Iressa”, Bull. Cancer 87, 873–876.
   Google Scholar
• Miller, M.J. (1998) “Differential effects of protein kinase A on Ras effector pathways”, Mol. Cell. Biol. 18, 3718–3726.
   PubMed Web of Science ®Google Scholar
• Mimeault, M. (2001) “Structure-function studies of ETS transcription factors”, Crit. Rev. Oncogene 11, 227–253.
   Google Scholar
• Mimeault, M. (2002) “New advances on structural and biological functions of ceramide in apoptotic/necrotic cell death and cancer”, FEBS Lett. 530, 9–16.
   PubMedGoogle Scholar
• Mimeault, M. and Bonenfant, D. (2002) “FTIR spectroscopic analyses of the temperature and pH influences on the stratum corneum lipid phase behaviors and interactions”, Talanta 56, 395–405.
   PubMedGoogle Scholar
• Mimeault, M., Pommery, N., Wattez, N., Bailly, C. and Henichart, J.P. (2002) “Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines. Implication of epidermal growth factor receptor down-regulation and ceramide production”, Prostate. Moasser, M.M., Basso, A., Averbuch, S.D. and Rosen, N. (2001) “The tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells”, Cancer Res. 61, 7184–7188.
   Google Scholar
• Moscatello, D.K., Holga-Madruga, M., Godwin, A.K., Ramirez, G., Gunn, G., Zoltick, P.W., Biegel, J.A., Hayes, R.L. and Wong, A.J. (1995) “Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors”, Cancer Res. 55, 5536–5539.
   PubMed Web of Science ®Google Scholar
• Moulder, S.L., Yakes, F.M., Muthuswamy, S.K., Bianco, R., Simpson, J.F. and Carlos, L.A. (2001) “Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo”, Cancer Res. 61, 8887–8895.
   PubMed Web of Science ®Google Scholar
• Myers, C.E. and Ghosh, J. (1999) “Lipoxygenase inhibition in prostate cancer”, Eur. Urol. 35, 395–398.
   PubMedGoogle Scholar
• Myers, R.B. and Grizzle, W.E. (1997) “Changes in biomarker expression in the development of prostatic adenocarcinoma”, Biotech. Histochem. 72, 86–95.
   PubMed Web of Science ®Google Scholar
• Myers, R.B., Oelschlager, D., Manne, U., Coan, P-N., Weiss, H. and Grizzle, W.E. (1999) “Androgenic regulation of growth factor and growth factor receptor expression in the CWR22 model of prostatic adenocarcinoma”, Int. J. Cancer 82, 424–429.
   PubMed Web of Science ®Google Scholar
• Naruse, I., Ohmori, T., Ao, Y., Fukumoto, H., Kuroki, T., Mori, M., Saijo, I. and Nishio, K. (2002) “Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD-1859) in an EGFR-expressing multidrug-resistance cell line in vitro and in vivo”, Int. J. Cancer 98, 310–315.
   PubMed Web of Science ®Google Scholar
• Nazareth, L.V. and Weigel, L. (1996) “Activation of the human androgen receptor through a protein kinase A signaling pathway”, J. Biol. Chem. 271, 19900–19907.
   PubMed Web of Science ®Google Scholar
• Nesterova, M., Noguchi, K., Park, Y.G., Lee, Y.N. and Cho-Chung, Y.S. (2000) “Compensatory stabilization of RIIbeta protein, cell cycle deregulation, and growth arrest in colon and prostate carcinoma cells by antisense-directed down-regulation of protein kinase A RIalpha protein”, Clin. Cancer Res. 6, 3434–3441.
   PubMedGoogle Scholar
• Nie, D., Tang, K., Szekeres, K., Li, L. and Hohn, K.V. (2000) “Eicosanoid regulation of angiogenesis in human prostate carcinoma and its therapeutic implications”, Ann. N.Y. Acad. Sci. 905, 165–176.
   PubMedGoogle Scholar
• Olapade-Olaopa, E.O., Moscatello, D.K., MacKay, E.H., Horsburgh, T., Sandhu, D.P., Terry, T.R., Wong, A.J. and Habib, F.K. (2000) “Evidence for the differential expression of a variant EGF receptor in human prostate cancer”, Br. J. Cancer 82, 186–194.
   PubMed Web of Science ®Google Scholar
• Payne, S.G., Brindley, D.N. and Guilbert, L.J. (1999) “Epidermal growth factor inhibits ceramide-induced apoptosis and lowers ceramide levels in primary placental trophoblasts”, J. Cell. Physiol. 180, 263–270.
   PubMedGoogle Scholar
• Peng, D., Fan, Z., Lu, Y., DeBlasio, T., Scher, H. and Mendelsohn, J. (1996) “Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KiP1 and induces G 1 arrest in prostatic carcinoma cell line DU145”, Cancer Res. 56, 3666–3669.
   PubMed Web of Science ®Google Scholar
• Pidgeon, G.P., Kandouz, M., Meram, A. and Hohn, K.V. (2002) “Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells”, Cancer Res. 62, 2721–2727.
   PubMed Web of Science ®Google Scholar
• Pierce, K.L., Luttrell, L.M. and Lefkowitz, R.J. (2001) “New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades”, Oncogene 20, 1532–1539.
   PubMed Web of Science ®Google Scholar
• Pirtskhalaishvili, G. and Nelson, J.B. (2000) “Endothelium-derived factors as paracrine mediators of prostate cancer progression”, Prostate 44, 77–87.
   Google Scholar
• Prenzel, N., Zwick, E., Daub, H., Leserer, M., Abraham, R., Wallasch, C. and Ullrich, A. (1999) “EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF”, Nature 402, 884–888.
   PubMed Web of Science ®Google Scholar
• Prenzel, N., Zwick, E., Leserer, M. and Ullrich, A. (2000) “Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification”, Breast Cancer Res. 2, 184–190.
   PubMedGoogle Scholar
• Putz, T., Culig, Z., Eder, I.E., Nessler-Menardi, C., Bartsch, G., Grunicke, H., Uberall, F. and Klocker, H. (1999) “Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathways in prostate cancer cell lines”, Cancer Res. 59, 227–233.
   PubMed Web of Science ®Google Scholar
• Ranson, M. (2002) “ZD1839 (Iressa): for more than just non-small cell lung cancer”, Oncologist 7, 16–24.
   PubMedGoogle Scholar
• Ripple, M.O., Henry, W.F., Rago, R.P. and Wilding, G. (1997) “Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells”, J. Natl Cancer Inst. 89, 40–48.
   PubMed Web of Science ®Google Scholar
• Rubenstein, M., Mirochnik, Y., Chou, P. and Guinan, P. (1998) “Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotides”, Methods Find Exp. Clin. Pharmacol. 20, 825–831.
   Google Scholar
• Sadar, M.D. (1999) “Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways”, J. Biol. Chem. 274, 7777–7783.
   PubMed Web of Science ®Google Scholar
• Sadar, M.D., Hussain, M. and Bruchovsky, N. (1999) “Prostate cancer: molecular biology of early progression to androgen independence”, Endocr. Relat. Cancer 6, 487–502.
   PubMed Web of Science ®Google Scholar
• Salido, M., Vilches, J., Lopez, A. and Roomans, G.M. (2002) “Neuropeptides bombesin and calcitonin inhibit apoptosis-related elemental changes in prostate carcinoma cell lines”, Cancer 94, 368–377.
   PubMedGoogle Scholar
• Schwartz, Jr, S., ,Caceres, C.,, Morote, J., De Torres, I., Rodriguez-Vallejo, J.M., Gonzalez J. and Reventos J. (1999) “Gains of the relative genomic content of erbB-1 and erbB-2 in prostate carcinoma and their association with metastasis”, Int. J Oncol. 14, 367–371.
   PubMedGoogle Scholar
• Seelan, R.S., Qian, C., Yokomizo, A., Bostwick, D.G., Smith, D.I. and Liu, W. (2000) “Human acid ceramidase is overexpressed but not mutated in prostate cancer”, Genes Chromosomes Cancer 29, 137–146.
   PubMed Web of Science ®Google Scholar
• Seetharam, S., Nodzenski, E., Beckett, M.A., Heimann, R., Cha, A., Margulies, I., Pastan, I., Kufe, D.W. and Weichselbaum, R.R. (1998) “Modulation of apoptotic response of a radiation-resistant human carcinoma by Pseudomonas exotoxin-chimeric protein”, Cancer Res. 58, 3215–3220.
   PubMedGoogle Scholar
• Seth, D., Shaw, K., Jazayeri, J. and Leedman, P.J. (1999) “Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancers cells”, Br. J. Cancer 80, 657–669.
   PubMedGoogle Scholar
• Shah, G.V., Rayford, W., Noble, M.J., Austenfeld, M., Weigel, J., Vamos, S. and Mebust, W.K. (1994) “Calcitonin stimulates growth of human prostate cancer cells through receptor-mediated increase in cyclic adenosine 30 50-monophosphates and cytoplasmic CA2+ transients”, Endocrinology 134, 596–602.
   PubMedGoogle Scholar
• Shaheen, R.M., Ahmad, A.S., Liu, W., Reinmuth, N., Jung, Y.D., Tseng, W.W., Drazan, K.E., Bucana, C.D., Hicklin, D.J. and Ellis, L.M. (2001) “Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors”, Br. J. Cancer 85, 584–589.
   PubMed Web of Science ®Google Scholar
• Shaul, P.W. and Anderson, R.G. (1998) “Role of plasmalemma caveolae in signal transduction”, Am. J. Physiol. 275, L843–L851.
   PubMedGoogle Scholar
• Sherwood, E.R., Van Dongen, J.L., Wood, C.G., Liao, S., Kozlowski, J.M. and Lee, C. (1998) “Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells”, Br. J. Cancer 77, 855–861.
   PubMed Web of Science ®Google Scholar
• Shureiqi, I. and Lippman, S.M. (2001) “Lipoxygenase modulation to reverse carcinogenesis”, Cancer Res. 61, 6307–6312.
   PubMed Web of Science ®Google Scholar
• Slichenmyer, W.J., Elliott, W.L. and Fry, D.W. (2001) “CI-1033, a panerbB tyrosine kinase inhibitor”, Semin. Oncol. 28, 80–85.
   PubMed Web of Science ®Google Scholar
• Sumitomo, M., Ohba, M., Asakuma, J., Asano, T., Kuroki, T. and Hayakawa, M. (2000) “Protein kinase C delta amplifies ceramide formation via mitochondrial signaling in prostate cancer cells”, J. Clin. Investig. 109, 827–836.
   Google Scholar
• Tanji, N., Kikugawa, T. and Yokoyama, M. (2000) “Immunohistochemical study of cyclooxygenase in prostatic adenocarcinoma; relationship to apoptosis and Bcl-2 Protein expression”, Anticancer Res. 20, 2313–2319.
   PubMed Web of Science ®Google Scholar
• Tanji, N., Aoki, K. and Yokoyama, M. (2001) “Growth factors: roles in andrology”, Arch. Androl. 47, 1–7.
   PubMedGoogle Scholar
• Teicher, B.A., Kakeji, Y., Ara, G., Herbst, R.S. and Northey, D. (1997) “Prostate carcinoma response to cytotoxic therapy: in vivo resistance”, In vivo 11, 453–461.
   PubMedGoogle Scholar
• Torring, N., Moller-Ernst, J.K., Lund, L., Nielsen, J.E., Djurhuus, J.C., Poulsen, S.S. and Nexo, E. (2002) “Possible autocrine loop of the epidermal growth factor system in patients with benign prostatic hyperplasia treated with finasteride: a placebo-controlled randomized study”, BJU Int. 89, 583–590.
   PubMedGoogle Scholar
• Tortora, G. and Ciardiello, F. (2000) “Targeting of epidermal growth factor receptor and protein kinase A: molecular basis and therapeutic applications”, Ann. Oncol. 11, 777–783.
   PubMedGoogle Scholar
• Tortora, G. and Ciardiello, F. (2002) “Protein Kinase A a target for novel integrated strategies of cancer therapy”, Ann. N.Y. Acad. Sci. 968, 139–147.
   PubMedGoogle Scholar
• Tortora, G., Damiano, V., Bianco, C., Baldassarre, G., Bianco, A.R., Lanfrancone, L., Pelicci, P.G. and Ciardiello, F. (1997) “The Rlalpha subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor”, Oncogene 14, 923–928.
   PubMed Web of Science ®Google Scholar
• Van Coppenolle, F., Le Bourhis, X., Carpentier, F., Delaby, G., Cousse, H., Raynaud, J.P., Dupouy, J.P. and Prevarskaya, N. (2000) “Pharmacological effects of the lipidosterolic extractofSerenoa repens (Permixon) onrat prostatehyperplasia inducedbyhyperprolactinemia: comparaison with finasteride”, Prostate 43, 49–58.
   Google Scholar
• Van Meer, G. and Lisman, Q. (2002) “Sphingolipid transport; rafts and translocators”, J. Biol. Chem. 277, 25855–25858.
   PubMed Web of Science ®Google Scholar
• Van Moorselaar, R.J. and Voest, E.E. (2002) “Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches”, Mol. Cell. Endocrinol. 197, 239–250.
   PubMedGoogle Scholar
• Von Haefen, C., Wieder, T., Gillissen, B., Starck, L., Graupner, V., Dorken, B. and Daniel, P.T. (2002) “Ceramide induces mitochondrial activation and apoptosis via a Bax-dependent pathway in human carcinoma cells”, Oncogene 21, 4009–4019.
   PubMed Web of Science ®Google Scholar
• Vossler, M.R., Yao, H., York, R.D., Pan, M.G., Rim, C.S. and Stork, P.J. (1997) “cAMP activates MAP kinase and Elk-1 through a B-Rad-, and Rap 1-dependent pathway”, Cell 89, 73–82.
   PubMed Web of Science ®Google Scholar
• Wang, X.Z., Beebe, J.R., Pwiti, L., Bielawska, A. and Smyth, M.J. (1999) “Aberrant sphingolipid signaling is involved in the resistance of prostate cancer cell lines to chemotherapy”, Cancer Res. 59, 5842–5848.
   PubMed Web of Science ®Google Scholar
• Wang, X., Ye, H. and Jiang, H. (2000) “Influence of androgen on Bcl-2 mRNA expression in BPH tissue”, Zhonghua Wai Ke Za Zhi. 38, 198–200.
   PubMedGoogle Scholar
• Ware, J.L. (1999) “Growth factor network disruption in prostate cancer progression”, Cancer Metast. Rev. 17, 443–447.
   Google Scholar
• Wartenberg, M., Fischer, K., Hescheler, J. and Sauer, H. (2000) “Redox regulation of P-glycoprotein-mediated multidrug resistance in multicellular prostate tumor spheroids”, Int. J. Cancer 85, 267–274.
   PubMedGoogle Scholar
• Werb, Z. and Yang, Y. (1998) “A cellular striptease act”, Science 282, 1279–1280.
   PubMedGoogle Scholar
• Worthylake, R., Opreslo, L.K. and Wiley, H.S. (1999) “ErbB-2 amplification inhibits down-regulation and induce constitutive activation of both ErbB-2 and epidermal growth factor receptors”, J. Biol. Chem. 274, 8865–8874.
   PubMed Web of Science ®Google Scholar
• Wu, X., Rubin, M., Fan, Z., Deblasio, T., Soos, T., Koff, A. and Mendelsonn, J. (1996) “Involvement of p27KiP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody”, Oncogene 12, 1397–1403.
   PubMed Web of Science ®Google Scholar
• Xia, W., Lau, Y.K., Zhang, H.Z., Xiao, F.Y., Jhonson, D.A., Liu, A.R., Li, L., Katz, R.L. and Hung, M.C. (1999) “Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the out-come of oral squamous cell carcinoma than any individual family members”, Clin. Cancer Res. 5, 4164–4174.
   PubMed Web of Science ®Google Scholar
• Xie, Y., Gibbs, T.C., Mukhin, Y.V. and Meir, K.E. (2002) “Role for 18:1 lysophosphatidic acid as an autocrine mediator in prostate cancer cells”, J. Biol. Chem. 277, 32516–32526.
   PubMedGoogle Scholar
• Yang, X.D., Jia, X.C., Corvala, J.R.F., Wang, P. and Davis, C.G. (2001) “Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy”, Crit. Rev. Oncol. Hematol. 38, 17–23.
   PubMed Web of Science ®Google Scholar
• Ye, D., Mendelsohn, J. and Fan, Z. (1999) “Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27KiP1 and costimulate proliferation of MDA Pca 2a and MDA Pca 2b prostate cancer cells”, Clin. Cancer Res. 5, 2171–2177.
   PubMed Web of Science ®Google Scholar
• Zi, X., Grasso, A.W., Kung, H.J. and Agarwal, R. (1998) “A flavonoid antioxidant silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells”, Cancer Res. 58, 1920–1929.
   PubMed Web of Science ®Google Scholar
• Zhuang, L., Lin, J., Lu, M.L., Solomon, K.R. and Freeman, M.R. (2002) “Cholesterol-rich lipid rafts mediate Akt-regulated survival in prostate cancer cells”, Cancer Res. 62, 2227–2231.
   PubMed Web of Science ®Google Scholar